Novartis Clozaril Blood Monitoring Requirements Relaxed By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA agrees to labeling change decreasing monitoring requirements for agranulocytosis to once monthly from twice a month. The agency asks Novartis to track agranulocytosis rates in the national registry.